文献速递肝病消化道肿瘤与早癌

混合AAV-piggyBac基因治疗在PFIC3小鼠模型中预防胆汁淤积性肝病并降低致瘤性

Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy.
PubMed 文献 · Hepatology · 2019-06-26

该研究在PFIC3的Abcb4-/-小鼠模型中,发现常规rAAV载体在已患病成年小鼠的肝转导明显减弱,而新生幼鼠单次注射混合rAAV-piggyBac载体可实现终身胆组分恢复、预防胆汁性肝硬化并大幅减少肿瘤发生,作者认为经进一步优化后具有人类临床转化潜力。

要点

  • 常规rAAV在已患病Abcb4-/-成年小鼠中肝转导明显减弱,在无病野生型成年鼠或发病前幼鼠中未见此现象。
  • 幼鼠注射非整合型rAAV因肝细胞增殖导致转基因表达不能持续。
  • 新生幼鼠单次注射混合rAAV-piggyBac载体可实现终身胆组分恢复、预防胆汁性肝硬化并大幅减少肿瘤发生。

核心结论

  • 混合载体系统结合rAAV的高转导效率与piggyBac转座酶介导的体细胞整合,可在PFIC3小鼠模型中实现人ABCB4的稳定体内表达并纠正幼年起病的慢性肝病。
  • 新生幼鼠单次注射混合载体可终身恢复胆汁组成、预防胆汁性肝硬化并大幅减少肿瘤发生。
  • 作者认为该混合rAAV-piggyBac转座子载体策略具有终身表型纠正和降低PFIC3致瘤性的能力,经进一步优化后具有人类临床转化潜力。

研究设计与样本

  • 研究在PFIC3的Abcb4-/-小鼠模型中进行,该模型幼鼠因胆道磷脂酰胆碱排泄受损而发展为进行性胆汁淤积性肝损伤,导致肝硬化和肝脏恶性肿瘤。
  • 研究开发了结合rAAV高转导效率与piggyBac转座酶介导体细胞整合的混合载体系统,用于在体内稳定表达人ABCB4。
  • 研究比较了常规rAAV策略在已患病成年Abcb4-/-小鼠、无病野生型成年小鼠及发病前同源幼鼠中的转导情况。

主要发现

  • 使用常规rAAV策略时,已患肝病的成年Abcb4-/-小鼠中rAAV转导明显减弱,而无病野生型成年小鼠或发病前同源幼鼠中未见此现象。
  • 将主要非整合型rAAV载体递送至幼鼠后,因生长中肝脏的肝细胞增殖导致持续转基因表达丢失。
  • 新生幼鼠单次注射混合载体导致终身胆汁组成恢复、胆汁性肝硬化预防和肿瘤发生大幅减少。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为该混合rAAV-piggyBac转座子载体策略具有终身表型纠正和降低PFIC3致瘤性的能力,经进一步优化后具有人类临床转化潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recombinant adeno-associated viral (rAAV) vectors are highly promising vehicles for liver-targeted gene transfer, with therapeutic efficacy demonstrated in preclinical models and clinical trials. Progressive familial intrahepatic cholestasis type 3 (PFIC3), an inherited juvenile-onset, cholestatic liver disease caused by homozygous mutation of the ABCB4 gene, may be a promising candidate for rAAV-mediated liver-targeted gene therapy. The Abcb4-/- mice model of PFIC3, with juvenile mice developing progressive cholestatic liver injury due to impaired biliary phosphatidylcholine excretion, resulted in cirrhosis and liver malignancy. Using a conventional rAAV strategy, we observed markedly blunted rAAV transduction in adult Abcb4-/- mice with established liver disease, but not in disease-free, wild-type adults or in homozygous juveniles prior to liver disease onset. However, delivery of predominantly nonintegrating rAAV vectors to juvenile mice results in loss of persistent transgene expression due to hepatocyte proliferation in the growing liver. Conclusion: A hybrid vector system, combining the high transduction efficiency of rAAV with piggyBac transposase-mediated somatic integration, was developed to facilitate stable human ABCB4 expression in vivo and to correct juvenile-onset chronic liver disease in a murine model of PFIC3. A single dose of hybrid vector at birth led to life-long restoration of bile composition, prevention of biliary cirrhosis, and a substantial reduction in tumorigenesis. This powerful hybrid rAAV-piggyBac transposon vector strategy has the capacity to mediate lifelong phenotype correction and reduce the tumorigenicity of progressive familial intrahepatic cholestasis type 3 and, with further refinement, the potential for human clinical translation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Siew SM, Cunningham SC, Zhu E, et al. Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy. Hepatology. 2019. PMID: 31099022. doi:10.1002/hep.30773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。